Subtopic Deep Dive

MicroRNAs as Cancer Biomarkers
Research Guide

What is MicroRNAs as Cancer Biomarkers?

MicroRNAs as cancer biomarkers refers to the use of circulating and tissue-specific miRNAs as non-invasive diagnostic, prognostic, and predictive markers in various human cancers.

Pioneering studies identified miRNA expression profiles that classify human cancers (Lü et al., 2005, 9531 citations). Circulating miRNAs in serum and other body fluids emerged as stable biomarkers for cancer diagnosis (Chen et al., 2008, 4522 citations; Weber et al., 2010, 2673 citations). Over 20 key papers document miRNA signatures across cancer types, validated by qPCR and expression arrays.

Curated Papers

Key Challenges

Why It Matters

miRNA signatures enable early cancer detection via liquid biopsies, reducing reliance on invasive tissue sampling (Chen et al., 2008). Prognostic panels predict therapy response in personalized oncology, as shown in glioma subtyping with miRNA integration (Brat et al., 2015). Calin and Croce (2006) signatures guide clinical trials for oncomiR-targeted therapies, impacting patient stratification in breast and lung cancers.

Key Research Challenges

Biomarker Stability in Fluids

Extracellular miRNAs require standardization for pre-analytical variables like vesicle isolation (Théry et al., 2018). Variability across serum, plasma, and saliva complicates reproducibility (Weber et al., 2010). Meta-analyses struggle with batch effects in expression data.

Validation Across Cohorts

Initial array-based profiles need qPCR confirmation in diverse populations (Lü et al., 2005). Tissue vs. circulating miRNA discordance hinders translation (Calin and Croce, 2006). Lack of large-scale prospective trials limits clinical adoption.

Specificity in Multi-Cancer Use

Overlapping miRNA signatures across cancer types reduce diagnostic precision (Esquela-Kerscher and Slack, 2006). Integration with genomic data like IDH mutations is incomplete (Brat et al., 2015). Functional validation of oncomiRs remains sparse.

Essential Papers

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

Clotilde Théry, Kenneth W. Witwer, Elena Aïkawa et al. · 2018 · Journal of Extracellular Vesicles · 10.6K citations

ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term co...

MicroRNA expression profiles classify human cancers

Jun Lü, Gad Getz, Eric A. Miska et al. · 2005 · Nature · 9.5K citations

MicroRNA signatures in human cancers

George A. Calin, Carlo M. Croce · 2006 · Nature reviews. Cancer · 7.6K citations

Oncomirs — microRNAs with a role in cancer

Aurora Esquela‐Kerscher, Frank J. Slack · 2006 · Nature reviews. Cancer · 7.0K citations

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

Jacob A. O’Brien, Heyam Hayder, Yara Zayed et al. · 2018 · Frontiers in Endocrinology · 4.9K citations

MicroRNAs (miRNAs) are a class of non-coding RNAs that play important roles in regulating gene expression. The majority of miRNAs are transcribed from DNA sequences into primary miRNAs and processe...

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

Xi Chen, Yi Ba, Lijia Ma et al. · 2008 · Cell Research · 4.5K citations

The Versatile Role of microRNA-30a in Human Cancer

Changqian Wang, Yang Xiang, Yitian Chen et al. · 2017 · Cellular Physiology and Biochemistry · 3.4K citations

MicroRNAs (miRNAs) are a group of noncoding RNA molecules of 20-23 nucleotides length that negatively regulate gene expressions in numerous cellular processes. Through complementary paring with tar...

Reading Guide

Foundational Papers

Start with Lü et al. (2005) for initial miRNA profiling in cancers, Calin and Croce (2006) for signatures, and Chen et al. (2008) for circulating biomarkers to grasp discovery and validation foundations.

Recent Advances

Study Théry et al. (2018) for EV standardization, Brat et al. (2015) for genomic integration in gliomas, and Peng and Croce (2016) for updated oncomiR roles.

Core Methods

Core techniques include miRNA microarrays (Lü et al., 2005), qPCR in body fluids (Weber et al., 2010), biogenesis pathway analysis (O’Brien et al., 2018), and EV isolation per MISEV2018 (Théry et al., 2018).

How PapersFlow Helps You Research MicroRNAs as Cancer Biomarkers

Discover & Search

Research Agent uses searchPapers('circulating miRNAs cancer biomarkers qPCR validation') to retrieve 50+ papers like Chen et al. (2008), then citationGraph maps forward citations from Lü et al. (2005) to recent validations, and exaSearch uncovers meta-analyses on serum miRNAs.

Analyze & Verify

Analysis Agent applies readPaperContent on Théry et al. (2018) for MISEV2018 guidelines, verifyResponse with CoVe cross-checks miRNA stability claims against Weber et al. (2010), and runPythonAnalysis processes expression array data from Lü et al. (2005) for differential expression stats with GRADE scoring on biomarker sensitivity.

Synthesize & Write

Synthesis Agent detects gaps in circulating vs. tissue miRNA validation post-Calin and Croce (2006), flags contradictions in oncomiR roles, while Writing Agent uses latexEditText for biomarker panel tables, latexSyncCitations for 20-paper bibliographies, and latexCompile for review manuscripts with exportMermaid diagrams of biogenesis pathways from O’Brien et al. (2018).

Use Cases

"Run meta-analysis on miR-21 expression in serum across lung cancer cohorts"

Research Agent → searchPapers → runPythonAnalysis (pandas meta-analysis on qPCR data from Chen et al. 2008 and similar) → GRADE-verified fold-change statistics and forest plots.

"Draft LaTeX review on miRNA signatures for glioma prognosis"

Synthesis Agent → gap detection → Writing Agent → latexEditText (signature tables) → latexSyncCitations (Brat et al. 2015) → latexCompile → PDF with integrated figures.

"Find code for miRNA expression analysis pipelines from cancer biomarker papers"

Research Agent → paperExtractUrls (Lü et al. 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R/qPCR normalization scripts for validation.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ miRNA biomarker papers, chaining searchPapers → citationGraph → readPaperContent → structured report with evidence tables from Calin and Croce (2006). DeepScan applies 7-step analysis with CoVe checkpoints to verify circulating miRNA stability per Théry et al. (2018). Theorizer generates hypotheses on miR-30a panels from Wang et al. (2017) integrated with glioma genomics (Brat et al., 2015).

Try Doxa for MicroRNAs as Cancer Biomarkers Research

Frequently Asked Questions

What defines microRNAs as cancer biomarkers?

miRNAs serve as biomarkers through dysregulated expression profiles in tissues and circulation, classifying cancers (Lü et al., 2005) and enabling non-invasive detection (Chen et al., 2008).

What are key methods for miRNA biomarker studies?

Expression microarrays identify signatures (Lü et al., 2005), qPCR validates in serum (Chen et al., 2008), and EV standardization follows MISEV2018 (Théry et al., 2018).

What are the most cited papers?

Lü et al. (2005, 9531 citations) on cancer classification, Calin and Croce (2006, 7556 citations) on signatures, and Chen et al. (2008, 4522 citations) on serum biomarkers.

What open problems exist?

Standardizing pre-analytics for EVs (Théry et al., 2018), improving multi-cancer specificity (Esquela-Kerscher and Slack, 2006), and prospective validation in diverse cohorts.